LON:AZN - AstraZeneca Share Price, Forecast & News

AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

AstraZeneca announced a dividend on Friday, February 14th. Shareholders of record on Thursday, February 27th will be given a dividend of GBX 146.40 per share on Monday, March 30th. This represents a yield of 1.92%. The ex-dividend date of this dividend is Thursday, February 27th. This is a positive change from AstraZeneca's previous dividend of $71.90. The official announcement can be seen at this link. View AstraZeneca's Dividend History.

16 equities research analysts have issued twelve-month price targets for AstraZeneca's stock. Their forecasts range from GBX 5,800 to £100. On average, they anticipate AstraZeneca's stock price to reach GBX 7,890.71 in the next twelve months. This suggests a possible upside of 4.9% from the stock's current price. View Analyst Price Targets for AstraZeneca.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 3 sell ratings, 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AstraZeneca.

News stories about AZN stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AstraZeneca earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for AstraZeneca.

Some companies that are related to AstraZeneca include GlaxoSmithKline (GSK), Bayer (BAYN), Dechra Pharmaceuticals (DPH), Hutchison China MediTech (HCM), Opthea (OPT), Medical Developments International (MVP), Mayne Pharma Group (MYX), Vectura Group (VEC), BEXIMCO PHARMAC/S GDR REGS (BXP), Eco Animal Health Group (EAH), Trilogy International Partners (TRL), Allergy Therapeutics (AGY), Recce Pharmaceuticals (RCE), NanoViricides (NNVC) and Pharmaxis (PXS).

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GlaxoSmithKline (GSK), Hain Celestial Group (HAIN), Vodafone Group (VOD), NVIDIA (NVDA), National Retail Properties (NNN), BP (BP), Marks and Spencer Group (MKS), Royal Dutch Shell (RDSB), Encana (ECA) and Philip Morris International (PM).

Shares of AZN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

One share of AZN stock can currently be purchased for approximately GBX 7,521.

AstraZeneca has a market capitalization of £98.69 billion and generates £24.14 billion in revenue each year. AstraZeneca employs 64,400 workers across the globe.View Additional Information About AstraZeneca.

The official website for AstraZeneca is http://www.astrazeneca.com/.

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The biopharmaceutical company can be reached via phone at +44-20-73045000.